Inegy (Simvastatin, Ezetimibe)

• Inegy is used to manage lipid disorders by targeting cholesterol synthesis and absorption pathways.
• Hypercholesterolemia: lowers LDL‑cholesterol in patients with elevated cholesterol levels.
• Mixed dyslipidemia: improves overall lipid profile by reducing LDL‑C and triglycerides while modestly raising HDL‑C.
• Cardiovascular risk reduction: used as part of therapy to decrease the risk of atherosclerotic events in high‑risk individuals.

• Simvastatin competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol biosynthesis, leading to up‑regulation of LDL receptors and increased clearance of circulating LDL. Ezetimibe selectively blocks the Niemann‑Pick C1‑like 1 (NPC1L1) transporter in the intestinal brush border, reducing absorption of dietary and biliary cholesterol. The combined effect results in a greater reduction of plasma LDL‑cholesterol than either agent alone.

Inegy may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Gastrointestinal discomfort: including nausea, abdominal pain, or diarrhea.
• Myalgia: muscle aches without significant CK elevation.
• Elevated liver enzymes: transient increases in ALT/AST.
• Dizziness: occasional light‑headedness.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with marked CK rise.
• Acute liver injury: significant hepatitis or hepatic failure.
• Severe allergic reactions: rash, angioedema, or anaphylaxis.
• Myopathy: muscle weakness with CK elevation.
• Pancreatitis: rare inflammation of the pancreas.

• Before initiating therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters.
• Liver function monitoring: obtain baseline and periodic ALT/AST levels.
• Renal impairment assessment: evaluate kidney function and adjust if necessary.
• Drug interaction review: avoid concomitant strong CYP3A4 inhibitors.
• Pregnancy and lactation: use only if potential benefit justifies the risk.
• Muscle symptom vigilance: discontinue if unexplained muscle pain with CK elevation occurs.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Inegy interacts with several medicines that can alter its safety or efficacy.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase simvastatin exposure → heightened myopathy risk.
• Gemfibrozil: synergistic effect on muscle toxicity.
• Cyclosporine: raises plasma concentrations of both components.
• High‑dose niacin: amplifies risk of hepatotoxicity and muscle injury.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Antacids containing aluminum or magnesium: can reduce ezetimibe absorption.
• Other statins (e.g., lovastatin): additive risk of muscle adverse events.